Loading organizations...
§ Private Profile · London, United Kingdom
AI platform developer offering biomedical knowledge analysis for life sciences R&D, focused on drug development and biomarker discovery.
Causaly is a London-based artificial intelligence company that develops a biomedical research platform to help life sciences organizations analyze scientific literature, interpret internal data, and accelerate drug discovery. The enterprise software processes over 100,000 documents daily, utilizing knowledge graphs and specialized agentic AI to automate complex research workflows such as target identification and biomarker discovery. The platform is currently utilized by twelve of the top twenty global pharmaceutical companies, with a diverse customer base that prominently features Gilead, the FDA, and the National Institute of Environmental Health Sciences. The company has raised $93 million in total venture capital funding, which includes a recent $60 million Series B round led by ICONIQ Growth with participation from Index Ventures and former Johnson & Johnson CEO Alex Gorsky. Causaly was founded in 2018 by Yiannis Kiachopoulos and Artur Saudabayev.
Causaly has raised $83.0M across 4 funding rounds.
Causaly has raised $83.0M in total across 4 funding rounds.
Causaly has raised $83.0M in total across 4 funding rounds.
Causaly's investors include Caroline Xie, Emerge, Entrepreneur First, Jonathan Becker, Index Ventures, La Famiglia, Marathon Venture Capital, RTP Global, Runa Capital, Visionaries Club, Charlie Songhurst, Alex Gorsky.
Causaly has raised $83.0M across 4 funding rounds. Most recently, it raised $60.0M Series B in July 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 1, 2023 | $60M Series B | Caroline XIE | Emerge, Entrepreneur First, Jonathan Becker, Index Ventures, LA Famiglia, Marathon Venture Capital, RTP Global, Runa Capital, Visionaries Club, Charlie Songhurst, Alex Gorsky, Olivier Pomel, European Bank For Reconstruction And Development, Pentech Ventures | Announced |
| May 20, 2021 | $17M Series A | Carlos Gonzalez Cadenas | European Bank For Reconstruction And Development, Marathon, Pentech Ventures | Announced |
| Nov 1, 2019 | $5M Series A | Ebrd Venture Capital, Marc Moens | Marathon Venture Capital, Runa Capital | Announced |
| Jul 1, 2018 | $1M Seed | Marathon Venture Capital | Emerge, Entrepreneur First, Runa Capital, Charlie Songhurst, DR. Alexander Moscho, Matt Clifford, Nadav Rosenberg, Emerge Venture LAB | Announced |
Causaly is a London-based technology company building an AI-powered platform for life sciences research and development, focused on accelerating drug discovery by transforming vast biomedical data into actionable insights.[1][2][3] It serves pharmaceutical companies, research institutions, and biomedical teams—such as 12 of the top 20 pharma giants including Novo Nordisk, Gilead, and Regeneron—by solving the problem of manual, time-intensive analysis of millions of publications and datasets through a high-precision knowledge graph with over 500 million facts, generative AI copilots, and secure enterprise data integration.[1][2][3][4] The platform automates multi-step workflows like target identification, hypothesis generation, and validation, delivering explainable, verifiable results that boost R&D productivity and reduce risk, with proven adoption evidenced by $60 million in Series B funding in 2023.[1][3][4]
Causaly was founded in 2018 by CEO Yiannis Kiachopoulos and CTO Artur Saudabayev, who leveraged their expertise in AI to create a platform that extracts and codifies scientific knowledge from natural language in publications.[3][4] The idea emerged from recognizing the bottleneck in biomedical research—drowning in unstructured data—and aimed to transform how scientists find, visualize, and collaborate on evidence, starting with drug discovery as the initial focus.[1][4] Early traction came quickly, with partnerships forming among leading pharma companies and research bodies like the FDA and National Institute of Environmental Health Sciences, leading to rapid expansion by 2023 when it secured $60 million in funding led by ICONIQ Growth, alongside Index Ventures and others.[3][4]
Causaly rides the wave of AI-driven scientific discovery in life sciences, where exploding biomedical data volumes demand automation to shorten drug development timelines from years to months.[1][3][5] Timing aligns with post-2023 AI maturity, including agentic systems and multimodal models, amplified by regulatory pressures for verifiable insights amid rising R&D costs (averaging $2.6 billion per drug).[3][4][5] Market forces like pharma's AI adoption—evident in partnerships with giants like Novo Nordisk—favor Causaly, as it influences the ecosystem by enabling faster therapies without competing in discovery, similar to tools like Benchling.[3][4] Its expansion into agentic AI positions it to shape standards for production-grade, evidence-backed AI in regulated industries.[5]
Causaly's launch of Agentic Research in September 2025 marks a pivot to autonomous AI agents that could redefine R&D scalability, building on its pharma dominance to target broader biomedical applications.[5] Trends like real-time evidence scanning, multimodal data integration, and regulatory AI validation will propel growth, potentially expanding to adjacent fields like environmental health.[2][5] Influence may evolve from tool provider to ecosystem orchestrator, fostering AI-native research norms and attracting further investment as adoption scales globally—transforming Causaly's vision of unprecedented breakthroughs into industry reality.[1][4]